AMRX:NYE-Amneal Pharmaceuticals Inc. Class A Common Stock (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 6.67

Change

-0.08 (-1.19)%

Market Cap

USD 2.08B

Volume

1.24M

Analyst Target

USD 4.11
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-0.96 (-0.50%)

USD 88.29B
HLN Haleon plc

-0.03 (-0.29%)

USD 48.57B
TAK Takeda Pharmaceutical Co Ltd A..

+0.19 (+1.33%)

USD 45.08B
RDY Dr. Reddy’s Laboratories Ltd..

-1.30 (-1.63%)

USD 13.46B
CTLT Catalent Inc

-0.12 (-0.20%)

USD 10.91B
ELAN Elanco Animal Health

+0.16 (+1.10%)

USD 7.26B
BHC Bausch Health Companies Inc

+0.05 (+0.60%)

USD 3.05B
CPHI China Pharma Holdings Inc

-0.01 (-3.86%)

USD 4.41M
YCBD cbdMD Inc

+0.01 (+2.61%)

USD 1.70M
EBS Emergent Biosolutions Inc

+0.41 (+4.59%)

N/A

ETFs Containing AMRX

LNGG Listed Funds Trust 10.84 % 0.00 %

+0.33 (+0%)

USD 0.74M
ZFC:CA BMO SIA Focused Canadian .. 6.77 % 0.00 %

N/A

CAD 0.06B
MVR:AU VanEck Vectors Australian.. 6.39 % 0.00 %

-0.06 (0%)

USD 0.43B
AUCO:SW L&G Gold Mining UCITS ETF.. 5.61 % 0.00 %

+0.73 (+0%)

N/A
ROYA 5.38 % 0.00 %

N/A

N/A
QRE:AU Beta Shares S&P/ASX 200Re.. 4.79 % 0.00 %

-0.05 (0%)

USD 0.21B
OZR:AU SPDR S&P/ASX 200 Resource.. 4.54 % 0.00 %

N/A

USD 0.17B
OAEM OneAscent Emerging Market.. 3.11 % 0.00 %

+0.31 (+0%)

N/A
FEM:LSE First Trust Emerging Mark.. 1.26 % 0.00 %

+30.50 (+0%)

USD 0.01B
FEMU:LSE First Trust Global Funds .. 1.26 % 0.00 %

+0.38 (+0%)

USD 0.01B
DLS WisdomTree International .. 0.00 % 0.58 %

+0.55 (+0%)

N/A
FEM First Trust Emerging Mark.. 0.00 % 0.80 %

+0.42 (+0%)

USD 0.44B
HAL:CA Global X Active Canadian .. 0.00 % 0.78 %

+0.17 (+0%)

CAD 0.13B
RING iShares MSCI Global Gold .. 0.00 % 0.39 %

-0.03 (0%)

USD 0.59B
IOGP:LSE iShares Oil & Gas Explora.. 0.00 % 0.00 %

+0.48 (+0%)

N/A
SPOG:LSE iShares V Public Limited .. 0.00 % 0.00 %

+42.75 (+0%)

N/A
ETLX:F L&G Gold Mining UCITS ETF 0.00 % 0.00 %

-0.29 (0%)

N/A
EXXW:F iShares Dow Jones Asia Pa.. 0.00 % 0.00 %

N/A

N/A
IQQX:F iShares Public Limited Co.. 0.00 % 0.00 %

N/A

N/A
IS0D:F iShares Oil & Gas Explora.. 0.00 % 0.00 %

N/A

N/A
ETLX:XETRA L&G Gold Mining UCITS ETF 0.00 % 0.00 %

+0.35 (+0%)

USD 0.13B
EXXW:XETRA iShares Dow Jones Asia Pa.. 0.00 % 0.00 %

-0.01 (0%)

USD 0.29B
IQQX:XETRA iShares Asia Pacific Divi.. 0.00 % 0.00 %

+0.06 (+0%)

USD 0.40B
IAPD:SW iShares Asia Pacific Divi.. 0.00 % 0.00 %

-0.11 (0%)

USD 0.46B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.88% 67% D+ 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.88% 67% D+ 70% C-
Trailing 12 Months  
Capital Gain 113.10% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 113.10% 100% F 98% N/A
Trailing 5 Years  
Capital Gain 0.15% 64% D 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.15% 57% F 34% F
Average Annual (5 Year Horizon)  
Capital Gain 30.77% 100% F 90% A-
Dividend Return 30.77% 100% F 89% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 85.49% 13% F 9% A-
Risk Adjusted Return 36.00% 69% C- 57% F
Market Capitalization 2.08B 31% F 65% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.